Your shopping cart is currently empty

Apigenin-7-glucuronide (Apigenin 7-O-glucuronide) possesses multiple activities, including antioxidant, anti-inflammatory, and aldose reductase inhibitory activities, it can inhibit MMP activities (IC50s: 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $40 | In Stock | In Stock | |
| 5 mg | $98 | In Stock | In Stock | |
| 10 mg | $156 | In Stock | In Stock | |
| 25 mg | $262 | In Stock | In Stock | |
| 50 mg | $389 | In Stock | In Stock | |
| 100 mg | $572 | In Stock | - | |
| 200 mg | $853 | In Stock | - | |
| 1 mL x 10 mM (in DMSO) | $108 | In Stock | In Stock |
| Description | Apigenin-7-glucuronide (Apigenin 7-O-glucuronide) possesses multiple activities, including antioxidant, anti-inflammatory, and aldose reductase inhibitory activities, it can inhibit MMP activities (IC50s: 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively). |
| Targets&IC50 | MMP13:0.27 μM, MMP9:17.52 μM, MMP8:22.39 μM, MMP3:12.87 μM |
| In vivo | Apigenin-7-O-β-D-glucuronide (AG) suppressed the release of nitric oxide (NO), prostaglandin E2 (PGE2), and tumour necrosis factor-α (TNF-α) in LPS-stimulated RAW 264.7 macrophages in a dose-dependent manner without affecting cell viability. Additionally, AG suppressed LPS-induced mRNA expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and TNF-α. AG treatment decreased the translocation of c-Jun into the nucleus and decreased activator protein-1 (AP-1)-mediated luciferase activity through the inhibition of both p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) phosphorylation [2]. |
| Synonyms | Apigenin 7-O-glucuronide |
| Molecular Weight | 446.36 |
| Formula | C21H18O11 |
| Cas No. | 29741-09-1 |
| Smiles | O[C@H]1[C@H](Oc2cc(O)c3c(c2)oc(cc3=O)-c2ccc(O)cc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O |
| Relative Density. | 1.737 g/cm3 |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (112.02 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.48 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.